mRNA-based vaccines for rapid response to emerging infectious disease outbreaks
1 Independent Researcher, Lagos, Nigeria.
2 Syracuse University, NY, USA.
3 Syracuse University, NY, USA.
Review Article
International Journal of Frontiers in Medicine and Surgery Research, 2024, 06(02), 097–105.
Article DOI: 10.53294/ijfmsr.2024.6.2.0049
Publication history:
Received on 07 October 2024; revised on 14 November 2024; accepted on 17 November 2024
Abstract:
This review examines the transformative role of mRNA vaccines in responding to emerging infectious disease outbreaks, with a focus on their unique mechanisms, rapid development potential, and demonstrated efficacy. The recent success of mRNA vaccines during the COVID-19 pandemic highlights their advantages over traditional vaccines, including adaptability, scalability, and a swift response time that is essential for pandemic preparedness. Despite these benefits, mRNA vaccine technology faces notable challenges, such as stringent cold chain requirements and public acceptance issues, which could impede global distribution and uptake. This paper provides a comprehensive overview of the mechanisms and advantages of mRNA vaccines, evaluates current technical and logistical barriers, and explores potential applications for future pandemic prevention. Recommendations are presented to enhance development processes, improve vaccine stability, and foster public trust. The insights in this review underscore the promise of mRNA technology as a pivotal tool for rapid, adaptive immunization, emphasizing the need for continued research and strategic investment to fully realize its potential in safeguarding public health.
Keywords:
mRNA vaccines; Pandemic preparedness; Vaccine development; Emerging infectious diseases; Vaccine distribution challenges; Public health security
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0